Código QR (código de barras bidimensional)

Prognostic impact of clinical factors for immune checkpoint inhibitor with or without chemotherapy in older patients with non-small cell lung cancer and PD-L1 TPS ≥ 50%

IntroductionThe proportion of older patients diagnosed with advanced-stage non-small cell lung cancer (NSCLC) has been increasing. Immune checkpoint inhibitor (ICI) monotherapy (MONO) and combination therapy of ICI and chemotherapy (COMBO) are standard treatments for patients with NSCLC and programm...

ver descrição completa

Na minha lista:
Principais autores: Shota Takei, Hayato Kawachi, Tadaaki Yamada, Motohiro Tamiya, Yoshiki Negi, Yasuhiro Goto, Akira Nakao, Shinsuke Shiotsu, Keiko Tanimura, Takayuki Takeda, Asuka Okada, Taishi Harada, Koji Date, Yusuke Chihara, Isao Hasegawa, Nobuyo Tamiya, Yuki Katayama, Naoya Nishioka, Kenji Morimoto, Masahiro Iwasaku, Shinsaku Tokuda, Takashi Kijima, Koichi Takayama
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2024-02-01
coleção:Frontiers in Immunology
Assuntos:
chemoimmunotherapy
immunochemotherapy
immune checkpoint inhibitor
non-small-cell lung cancer
PD-L1
Acesso em linha:https://www.frontiersin.org/articles/10.3389/fimmu.2024.1348034/full
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados